Comparison of frequency of hemorrhagic stroke in patients <75 years versus ≥75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions

American Journal of Cardiology

Volumn 93, Issue 3, 2004, Pages 346-349

  Iakovou, Ioannis ^a   Dangas, George ^a   Mintz, Gary S ^a   Mehran, Roxana ^a   Lansky, Alexandra J ^a   Aymong, Eve D ^a   Nikolsky, Eugenia ^a   Vagaonescu, Tudor ^a   Glasser, Lynne A ^a   Stone, Gregg W ^a   Leon, Martin B ^a   Moses, Jeffrey W ^a  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGE; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CINEANGIOCARDIOGRAPHY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY STENT; DATA BASE; HEART CATHETERIZATION; HOSPITAL PATIENT; HUMAN; INFORMATION PROCESSING; INFORMATION RETRIEVAL; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; METHODOLOGY; PREVALENCE; PRIORITY JOURNAL; SAMPLE SIZE; SENESCENCE; STATISTICAL ANALYSIS; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 10744225945     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.10.018     Document Type: Article

References (20)

1. Lefkovits J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559.
2. Dangas G., Colombo A. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization. Am Heart J. 138:(suppl):1999;S16-S23.
3. Batchelor W.B., Anstrom K.J., Muhlbaier L.H., Grosswald R., Weintraub W.S., O'Neill W.W., Peterson E.D. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions results in 7472 octogenarians . J Am Coll Cardiol. 36:2000;723-730.
4. Graham M.M., Ghali W.A., Fari P.D., Galbraith P.D., Norris C.M., Knudtson M.L. Survival after coronary revascularization in the elderly. Circulation. 105:2002;2378-2384.
5. Pepine C.J., Holmes D.R. Jr. Coronary artery stents. American College of Cardiology. J Am Coll Cardiol. 28:1996;782-794.
6. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
7. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 350:1997;1689-1696.
8. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 339:1998;436-443.
9. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
10. Popma J.J., Bashore T.D. Qualitative and quantitative angiography. Topol E. Textbook of Interventional Cardiology. 1994;1052-1068 WB Saunders, Philadelphia.
11. Mehran R., Dangas G., Mintz G.S., Lansky A.J., Pichard A.D., Satler L.F., Kent K.M., Stone G.W., Leon M.B. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions intravascular ultrasound study of 2256 patients . Circulation. 101:2000;604-610.
12. Chesebro J.H., Knatterud G., Roberts R., Borer J., Cohen L.S., Dalen J., Dodge H.T., Francis C.K., Hillis D., Ludbrook P. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge . Circulation. 76:1987;142-154.
13. Saucedo J.F., Mehran R., Dangas G., Hong M.K., Lansky A., Kent K.M., Satler L.F., Pichard A.D., Stone G.W., Leon M.B. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol. 35:2000;1134-1141.
14. De Gregorio J., Kobayashi Y., Albiero R., Reimers B., Di Mario C., Finci L., Colombo A. Coronary artery stenting in the elderly short-term outcome and long-term angiographic and clinical follow-up . J Am Coll Cardiol. 32:1998;577-583.
15. Wennberg D.E., Malenka D.J., Sengupta A., Lucas F.L., Vaitkus P.T., Quinton H., O'Rourke D., Robb J.F., Kellett M.A. Jr, Shubrooks S.J. Jr, et al. Percutaneous transluminal angioplasty in the elderly epidemiology, clinical risk factors, and in-hospital outcomes . Am Heart J. 137:1999;639-645.
16. Cote A.V., Berger P.B., Holmes D.R. Jr, Scott C.G., Bell M.R. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Mayo Clin Proc. 76:2001;890-896.
17. Mak K.H., Effron M.B., Moliterno D.J. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. Drugs Aging. 16:2002;179-187.
18. Qureshi A.I., Saad M., Zaidat O.O., Suarez J.I., Alexander M.J., Fareed M., Suri K., Ali Z., Hopkins L.N. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke. 33:2002;1916-1918.
19. Cheitlin M.D., Zipes D.P. Cardiovascular disease in the elderly. Braunwalk E., Zipes D.P., Libby P. Heart Disease. 6th:2001;2020-2021 W.B. Saunders.
20. Curb J.D., Abbott R.D., MacLean C.J., Rodriguez B.L., Burchfiel C.M., Sharp D.S., Ross G.W., Yano K. Age-related changes in stroke risk in men with hypertension and normal blood pressure. Stroke. 27:1996;819-824.